Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;96(7):2105-11.
doi: 10.1210/jc.2011-0305. Epub 2011 May 11.

Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH

H Tala  1 , R Robbins, J A Fagin, S M Larson, R M Tuttle
Affiliations

Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH

H Tala et al. J Clin Endocrinol Metab. 2011 Jul.

Abstract

Context: Elevated levels of TSH markedly enhance the effectiveness of radioiodine (RAI) therapy in metastatic thyroid cancer.

Objective: The objective of the study was to compare short-term overall survival in thyroid cancer patients with RAI-avid distant metastases prepared for RAI therapy with either traditional thyroid hormone withdrawal (THW) or recombinant human TSH (rhTSH) stimulation.

Design: This was a retrospective chart review.

Setting: The study was conducted at a tertiary care comprehensive cancer center.

Patients: Patients included 175 patients with RAI avid metastatic disease to lung and/or bone.

Interventions: In 58 patients, all RAI treatments (remnant ablation and therapy of metastatic disease) were done with rhTSH stimulation. In 35 patients, all RAI treatments were done after THW. In 82 patients, THW was used for initial RAI treatment(s) with subsequent administered activities given after rhTSH stimulation.

Main outcome measure: Overall survival was measured.

Results: After a median follow-up of 5.5 yr, there were no significant differences in overall survival between patients prepared for RAI therapy with rhTSH alone, THW alone, or THW followed by rhTSH (Kaplan-Meier analysis, P = 0.80). In a multivariate analysis that included clinicopathological features and method of preparation (rhTSH or TWH), only age at diagnosis was an independent predictor of overall survival.

Conclusions: Preparation for RAI therapy using either THW or rhTSH stimulation was associated with similar 5-yr overall survival rates in patients with RAI avid thyroid cancer metastases to lung or bone.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overall survival curves based on method of preparation for RAI therapy. rhTSH-only patients had all RAI treatments (ablation and any additional therapies) done with rhTSH preparation. Similarly, THW-only patients had all treatments done after THW. The final group had at least one initial treatment (either ablation or treatment of DM) with TWH followed by one or more additional treatments using rhTSH stimulation (THW followed by rhTSH). Overall survival was similar in all three groups (P = 0.80 by Kaplan-Meier analysis).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Durante C ,Haddy N ,Baudin E ,Leboulleux S ,Hartl D ,Travagli JP ,Caillou B ,Ricard M ,Lumbroso JD ,De Vathaire F ,Schlumberger M. 2006. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892–2899 - PubMed
    1. Robbins RJ ,Schlumberger MJ. 2005. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46(Suppl 1):28S–37S - PubMed
    1. Cooper DS ,Doherty GM ,Haugen BR ,Haugen BR ,Kloos RT ,Lee SL ,Mandel SJ ,Mazzaferri EL ,McIver B ,Pacini F ,Schlumberger M ,Sherman SI ,Steward DL ,Tuttle RM. 2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214 - PubMed
    1. Pilli T ,Brianzoni E ,Capoccetti F ,Castagna MG ,Fattori S ,Poggiu A ,Rossi G ,Ferretti F ,Guarino E ,Burroni L ,Vattimo A ,Cipri C ,Pacini F. 2007. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542–3546 - PubMed
    1. Tuttle RM ,Lopez N ,Leboeuf R ,Minkowitz SM ,Grewal R ,Brokhin M ,Omry G ,Larson S. 2010. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 20:257–263 - PubMed

Publication types

MeSH terms